Faculty

Gagandeep Singh, MD, FACS (Activity Course Director)

Head, Hepatobiliary and Pancreatic Surgery; Liver and Pancreatic Surgeon; Chief, Division of Surgical Oncology, Department of Surgery; Vice Chair and Clinical Professor, Department of Surgery; City of Hope, Duarte, California

Disclosures

Gagandeep Singh, MD, FACS, has disclosed no relevant financial relationships.
Off-label discussion: Gagandeep Singh, MD, FACS, None.

Jonathan Kessler, MD (Activity Faculty)

Assistant Clinical Professor, Department of Diagnostic Radiology; Radiologist; City of Hope, Duarte, California

Disclosures

Jonathan Kessler, MD, has disclosed no relevant financial relationships.
Off-label discussion: Jonathan Kessler, MD, discloses off label/investigational use of Yttrium-90 microspheres.

Additional Planners/Reviewers

CME Committee/Planners Nothing to Disclose: Joseph C. Alvarnas, MD; Patricia Aoun, MD; Chandana Banerjee, MD; Kathleen Blazer, MS, EdD; Abigail Wong Grigsby, JD; Lara Hovsepian, MA, PPS; Patricia Kassab, RN, MS, CTHQ; Carl Kildoo, PharmD; Evelyn Kwong, BA; Andrea Lynch, MLIS; Linda H. Malkas, PhD; Mary Mendelsohn, RN, MSN; Robert Morgan, MD; Anna Pawlowska, MD; Margaret Robles, BBA; Crystal Saavedra, BS; Raynald A. Samoa, MD; Sara Scorcia, BSW; Gagandeep P. Singh, MD; Michael Sullivan, MD; Rose Virani, RNC, MHA, OCN, FPCN; Jeffrey Weitzel, MD

CME Committee/Planners Disclosed the following:

Laura Brown, MLS- Stock/Shareholder in Johnson & Johnson, Procter & Gamble and Amazon

Joseph Chao, MD- Grant/Research Support from Merck, Consultant for Lilly, Five Prime Therapeutics and Boston Biomedical

Kim Margolin, MD- Grant/Research Support from Merck, Altor, Amgen and Bristol-Myers Squibb, Consultant for ImaginAb, Pfizer, Amgen, Lion, Spectrum and Prometheus;

Sumanta Pal, MD- Grant/Research Support from Pfizer, Consultant for Novartis, Pfizer, Exelixis, Ipsen and Genentech, On the Speakers Bureau for Genentech

CME

How the Experts Treat Neuroendocrine Tumors

Authors: Gagandeep Singh, MD, FACS (Activity Course Director); Jonathan Kessler, MD (Activity Faculty)
CME Released: 2/27/2017
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 2/27/2018

Start Activity

Target Audience and Goal Statement

This educational program is directed toward gastroenterologists, internists, surgeons, medical oncologists, radiation oncologists, surgical oncologists and other allied healthcare professionals interested in the treatment of patients with neuroendocrine tumors.

Neuroendocrine tumors, while uncommon, are increasing in frequency. Because of the many cell types from which they derive, these tumors present in diverse manifestations, from symptoms consistent with high-grade malignancy to very indolent tumors that manifest as endocrine disturbances due to the secretion of multiple hormones. It is common for the diagnosis to be delayed for years and the classic symptoms to be attributed to more common diagnoses. This results in progression of early stage disease to late stage incurable disease. Psychiatric manifestations may also be present. In the past decade, much has been learned about the treatment of these neoplasms. Increased knowledge of the contribution of surgery to palliation and longevity is now understood. New systemic agents have been developed with indications for long-term control of these cancers. It is important for healthcare practitioners caring for these patients to have an increased understanding of their presentation and treatment.

Upon completion of this activity, participants will be able to:

Review the newer indications and results of surgical approaches to neuroendocrine neoplasms
Review indications for systemic therapy of these tumors

Faculty

Gagandeep Singh, MD, FACS (Activity Course Director)

Head, Hepatobiliary and Pancreatic Surgery; Liver and Pancreatic Surgeon; Chief, Division of Surgical Oncology, Department of Surgery; Vice Chair and Clinical Professor, Department of Surgery; City of Hope, Duarte, California

Disclosures

Gagandeep Singh, MD, FACS, has disclosed no relevant financial relationships.
Off-label discussion: Gagandeep Singh, MD, FACS, None.

Jonathan Kessler, MD (Activity Faculty)

Assistant Clinical Professor, Department of Diagnostic Radiology; Radiologist; City of Hope, Duarte, California

Disclosures

Jonathan Kessler, MD, has disclosed no relevant financial relationships.
Off-label discussion: Jonathan Kessler, MD, discloses off label/investigational use of Yttrium-90 microspheres.

Additional Planners/Reviewers

CME Committee/Planners Disclosed the following:

Laura Brown, MLS- Stock/Shareholder in Johnson & Johnson, Procter & Gamble and Amazon

Joseph Chao, MD- Grant/Research Support from Merck, Consultant for Lilly, Five Prime Therapeutics and Boston Biomedical

Kim Margolin, MD- Grant/Research Support from Merck, Altor, Amgen and Bristol-Myers Squibb, Consultant for ImaginAb, Pfizer, Amgen, Lion, Spectrum and Prometheus;

Sumanta Pal, MD- Grant/Research Support from Pfizer, Consultant for Novartis, Pfizer, Exelixis, Ipsen and Genentech, On the Speakers Bureau for Genentech

Accreditation Statements

For Physicians

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

City of Hope designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

City of Hope: [email protected] or 626.218.5622.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

How the Experts Treat Neuroendocrine Tumors

Authors: Gagandeep Singh, MD, FACS (Activity Course Director); Jonathan Kessler, MD (Activity Faculty)Faculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CME Released: 2/27/2017

Valid for credit through: 2/27/2018

processing....

This CME activity is based on the slides and lectures presented by the faculty at the conference, How the Experts Treat Neuroendorcrine Tumors, on April 9, 2016, at the Argyros Auditorium, Duarte, California

CME Information Download Slides

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.